FDA 483 - Intas Pharmaceuticals Ltd.

Intas Pharmaceuticals Ltd. received a Form 483 citing significant deficiencies across multiple areas, including data integrity issues in laboratory records and computer systems, inadequate control over records, insufficient investigation procedures, and failures in aseptic processing controls. The observations highlight a systemic lack of adherence to established procedures and proper quality oversight, impacting product quality and data reliability.